# India Neuropsychiatric Disorders Treatment Market > India Neuropsychiatric Disorders Treatment Market Research Report By Type (Degenerative Diseases, Neurotic Disorders, Psychosis, Others), By Application (Shock Treatment, Drug Treatment, Others), and By End User (Hospitals, Clinics, Research Centre’s, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 10.25% - **2024:** $ 9.06 Billion - **2025:** $ 9.99 Billion - **2035:** $ 26.5 Billion - **Key Players:** Johnson & Johnson (US), Pfizer (US), Eli Lilly and Company (US), AstraZeneca (GB), Bristol-Myers Squibb (US), Novartis (CH), Sanofi (FR), Roche (CH), Otsuka Pharmaceutical (JP) **Report ID:** MRFR/HC/43519-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/india-neuropsychiatric-disorders-treatment-market-45199 --- ## Market Summary ## **India Neuropsychiatric Disorders Treatment Market Overview** As per MRFR analysis, the India Neuropsychiatric Disorders Treatment Market Size was estimated at 6.58 (USD Billion) in 2023. The India Neuropsychiatric Disorders Treatment Market Industry is expected to grow from 7.25(USD Billion) in 2024 to 23.75 (USD Billion) by 2035. The India Neuropsychiatric Disorders Treatment Market CAGR (growth rate) is expected to be around 11.39% during the forecast period (2025 - 2035) **Key India Neuropsychiatric Disorders Treatment Market Trends Highlighted** The India Neuropsychiatric Disorders Treatment Market is experiencing significant growth driven by the increasing prevalence of mental health disorders among the Indian population. Growing awareness regarding mental health issues and the need for effective treatment is leading to higher demand for various therapies and medications. Government initiatives, such as the National Mental Health Programme, have also focused on improving mental health services, which serves as a crucial market driver. Additionally, the stigma surrounding neuropsychiatric disorders is gradually diminishing, enabling more individuals to seek help and thereby increasing treatment uptake. Teletherapy and mobile healthcare apps are two modern approaches to treatment that have embraced technology. This trend is especially meaningful to India because people in rural areas lack access to traditional healthcare facilities. These advancements provide new ways of treatment that address many needs as well as make it easier to reach a greater audience. Additionally, the growing investment in R&D to find new drugs and treatment methods demonstrates an interest in developing personalized treatment plans. There is also a change in focus towards developing mental health literacy programs for the general population aimed at the early diagnosis of neuropsychiatric disorders and the timely provision of needed care. The combination of these factors creates opportunities for the country's stakeholders to respond to the need for greater mental health services and resources, which can be effectively tapped. India has made significant changes to its mental healthcare infrastructureand is now capable of providing comprehensive care. **India Neuropsychiatric Disorders Treatment Market Drivers** **Rising Incidence of Mental Health Disorders** The prevalence of mental health disorders in India has reached alarming levels, with estimates suggesting that nearly 14% of the population suffers from various neuropsychiatric conditions such as depression, anxiety, and schizophrenia. This figure translates to over 150 million individuals requiring treatment. The National Mental Health Survey by the Government of India indicates a significant rise in cases over the past decade, with mental health conditions projected to contribute substantially to the overall disease burden in the country.With organizations like the Indian Psychiatric Society advocating for increased awareness and treatment accessibility, the India Neuropsychiatric Disorders Treatment Market Industry is poised for notable growth as more individuals seek medical help. **Government Initiatives and Policy Support** The Indian government has been proactive in addressing mental health issues through various initiatives and policy frameworks. The launch of the 'Mental Healthcare Act' in 2017 aims to provide comprehensive mental health services and ensure patients' rights. Additionally, the National Health Mission encourages the integration of mental health services into primary healthcare. These initiatives have led to an improved understanding of neuropsychiatric disorders and increased funding for treatment facilities.The engagement of healthcare organizations and NGOs such as the Vandrevala Foundation has further enhanced the capacity for research and treatment options, amplifying the growth potential of the India Neuropsychiatric Disorders Treatment Market Industry. **Growing Awareness and Reduced Stigma** There is a significant shift in societal attitudes towards mental health in India, thanks to comprehensive awareness campaigns led by various organizations. Initiatives by the World Health Organization and local NGOs have played a pivotal role in educating the public about neuropsychiatric disorders. Public figures and celebrities openly discussing their mental health struggles have further contributed to reducing stigma. As awareness increases, more individuals are willing to seek help, resulting in a rising demand for treatment options.The India Neuropsychiatric Disorders Treatment Market Industry stands to benefit as a wider segment of the population seeks institutional and therapeutic interventions for their mental health needs. **India Neuropsychiatric Disorders Treatment Market Segment Insights** **Neuropsychiatric Disorders Treatment Market Type Insights** The India Neuropsychiatric Disorders Treatment Market is diverse and can be categorized into several key types that play significant roles in addressing various conditions impacting mental health. Among these types, Degenerative Diseases are gaining attention due to their long-term effects and increasing prevalence within the Indian population, particularly among older adults who face cognitive decline and other debilitating symptoms. Neurotic Disorders, encompassing anxiety and mood-related issues, have seen a rise in awareness and diagnosis, fueled by changing societal attitudes towards mental health, thus creating a substantial demand for effective treatments.Psychosis remains a crucial focus area as it presents severe challenges for both patients and their families, making comprehensive treatment approaches vital. Additionally, the "Others" category encompasses various lesser-known conditions that still significantly burden the healthcare system, highlighting the need for innovative treatment solutions and awareness in the community. The India Neuropsychiatric Disorders Treatment Market segmentation not only showcases the diverse conditions but also underscores the evolving understanding of mental health in India, where cultural stigmas are slowly being replaced by a drive for better healthcare access and support.As the country's healthcare system continues to adapt, there exist ample opportunities for growth in treatment modalities across all these types, ensuring that various subsets of the population receive the necessary care for their unique challenges. Rising healthcare expenditure and government initiatives targeting mental health policies are likely to propel further investment in this market segment, which is reflective of a broader trend towards prioritizing mental health as an integral part of holistic healthcare in India. **Neuropsychiatric Disorders Treatment Market Application Insights** The Application segment within the India Neuropsychiatric Disorders Treatment Market is pivotal in addressing the diverse needs of patients suffering from various neuropsychiatric conditions. This segment includes techniques like Shock Treatment, which is noteworthy for its historical significance and continued use in treatment protocols for severe depression and other disorders, proving to be a crucial tool in psychiatric care. Drug Treatment remains a cornerstone in this segment, reflecting the growing reliance on pharmaceuticals to manage symptoms effectively.As the prevalence of neuropsychiatric disorders rises, the demand for innovative drug therapies expands, highlighting the need for ongoing research and development in this field. Other methods complement these primary approaches, providing additional avenues for treatment and emphasizing the market's extensive nature. Overall, the dynamics of the India Neuropsychiatric Disorders Treatment Market segmentation indicate a rapidly evolving landscape driven by both patient needs and advancements in medical science, making the Application segment integral for enhancing therapeutic outcomes.The current landscape showcases the necessity of tailored treatment plans for the diverse patient population, ensuring that every individual receives the most effective care based on their unique conditions. **Neuropsychiatric Disorders Treatment Market End User Insights** The End User segment of the India Neuropsychiatric Disorders Treatment Market is characterized by its diverse categories, which include Hospitals, Clinics, Research Centres, and others. Hospitals play a crucial role in providing comprehensive care for patients with neuropsychiatric disorders, addressing a wide range of conditions such as depression, anxiety, and more severe psychiatric illnesses. Clinics, on the other hand, typically offer specialized outpatient services, focusing on preventative care and early intervention, greatly enhancing patient accessibility to treatment.Research Centres contribute significantly to the landscape by facilitating innovative treatments and clinical trials, which is important for advancing knowledge in neuropsychiatric conditions in India. The growing awareness and destigmatization surrounding mental health is driving demand across these sectors, while an increase in healthcare funding and government initiatives further support market growth. Additionally, the infrastructure growth in urban areas provides opportunities to expand services while challenges such as the need for trained professionals and patient follow-up protocols persist.Overall, the segmentation reveals a complex interplay of healthcare facilities tailored to address the unique needs of those suffering from neuropsychiatric disorders across India. **India Neuropsychiatric Disorders Treatment Market Key Players and Competitive Insights** The India Neuropsychiatric Disorders Treatment Market has observed significant growth in recent years, fueled by an increasing prevalence of various mental health disorders and a growing awareness of mental health issues among the general population. This market is characterized by a dynamic competitive landscape, with numerous key players striving to establish their presence through innovative treatment options, robust marketing strategies, and partnerships with healthcare institutions. Given the rising demand for effective neuropsychiatric therapies, companies are investing substantially in research and development to introduce new treatment modalities and improve existing ones. Furthermore, the regulatory environment in India is evolving, prompting companies to adapt their approaches to meet compliance standards while catering to the specific needs of Indian patients.GSK India holds a prominent position in the India Neuropsychiatric Disorders Treatment Market, leveraging its extensive experience and established presence in the pharmaceutical sector. The company is recognized for its strong portfolio of neuropsychiatric medications that address a wide range of conditions, including depression, anxiety disorders, and schizophrenia. GSK India's strengths lie in its commitment to research and its ability to bring innovative medications to the market. With a well-structured distribution network and strong partnerships with healthcare professionals, GSK India has been successful in penetrating a wide audience. The company's focus on enhancing patient access to treatments, coupled with its robust clinical trials, contributes significantly to its competitive edge in the neuropsychiatric treatment arena.Sawai Pharmaceuticals has made considerable strides in the India Neuropsychiatric Disorders Treatment Market, primarily by focusing on innovative therapies and expanding its product offerings. The company emphasizes the development of key products that cater to various mental health challenges, ensuring they meet the local population's needs. Sawai Pharmaceuticals benefits from strong research capabilities and a proactive approach to mergers and acquisitions, which has bolstered its market presence and diversified its treatment portfolio. By collaborating with local healthcare providers and investing in education programs aimed at reducing stigma around neuropsychiatric disorders, Sawai Pharmaceuticals strengthens its brand reputation in India. Its ongoing commitment to understanding patient needs and expanding access to effective treatments further solidifies its position in a competitive market environment. **Key Companies in the India Neuropsychiatric Disorders Treatment Market Include** **India Neuropsychiatric Disorders Treatment Market Industry Developments** The India Neuropsychiatric Disorders Treatment Market is witnessing significant developments, particularly in the pharmaceutical sector. Companies such as Sun Pharmaceutical Industries and Cipla have recently expanded their product portfolios to include innovative psychiatric treatments, aiming to address the rising demand caused by increasing awareness and prevalence of mental health issues. Notably, in August 2023, Wockhardt announced a strategic partnership to enhance drug delivery mechanisms for neuropsychiatric medications, showcasing the focus on research and development in this sector. Additionally, in May 2022, Zydus Cadila launched a new formulation targeting depression and anxiety disorders, reflecting the growing emphasis on mental health treatments in India. Mergers and acquisitions have also marked the landscape; in September 2023, Piramal Enterprises acquired a specialty pharmaceutical unit from Abbott, India, which could potentially enhance its neuropsychiatric offerings. The growth in the market valuation of companies like Dr. Reddy's Laboratories and Intas Pharmaceuticals is indicative of the sector's vitality, with significant investments being funneled into R&D. The increasing recognition of mental health issues is likely to continue influencing the competitive dynamics among leading players such as GSK India, Torrent Pharmaceuticals, and Aurobindo Pharma, shaping the future of neuropsychiatric treatment in India. **India Neuropsychiatric Disorders Treatment Market Segmentation Insights** ## Market Drivers ### Increase in Healthcare Expenditure The increase in healthcare expenditure in India is a significant factor driving the neuropsychiatric disorders-treatment market. With the healthcare budget expanding, more resources are allocated to mental health services. Reports indicate that healthcare spending in India is projected to reach approximately $370 billion by 2025, which includes investments in mental health infrastructure and services. This financial commitment is likely to enhance the availability and quality of treatment options for neuropsychiatric disorders. As healthcare facilities improve and more professionals enter the field, the neuropsychiatric disorders-treatment market is expected to experience robust growth, catering to the needs of an increasingly health-conscious population. ### Advancements in Treatment Technologies Technological innovations in treatment methodologies are significantly influencing the neuropsychiatric disorders-treatment market. The introduction of novel therapies, such as neuromodulation techniques and digital therapeutics, has transformed the landscape of mental health treatment. For instance, the use of transcranial magnetic stimulation (TMS) has shown promising results in treating depression and anxiety disorders. Furthermore, the integration of artificial intelligence in diagnostic tools enhances the accuracy of mental health assessments. As these technologies become more accessible, they are expected to drive market growth. The Indian healthcare sector is increasingly adopting these advancements, indicating a shift towards more effective and personalized treatment options in the neuropsychiatric disorders-treatment market. ### Government Initiatives and Policy Support Government initiatives aimed at improving mental health services are crucial for the neuropsychiatric disorders-treatment market. The Indian government has launched several policies to enhance mental health care, including the National Mental Health Programme, which focuses on providing comprehensive mental health services. Additionally, increased funding for mental health research and treatment facilities is anticipated to bolster the market. The government's commitment to reducing the stigma associated with mental health issues encourages more individuals to seek treatment. As a result, the neuropsychiatric disorders-treatment market is likely to benefit from these supportive policies, leading to improved access to care and a broader range of treatment options. ### Growing Prevalence of Mental Health Disorders The rising incidence of mental health disorders in India is a primary driver for the neuropsychiatric disorders-treatment market. Reports indicate that approximately 14% of the Indian population experiences some form of mental health issue, which translates to over 150 million individuals. This alarming statistic underscores the urgent need for effective treatment options. As awareness increases, more individuals seek help, thereby expanding the market. The government has also initiated various programs aimed at mental health awareness, which further propels the demand for treatment solutions. Consequently, the neuropsychiatric disorders-treatment market is likely to witness substantial growth as healthcare providers strive to meet the needs of this growing patient population. ### Rising Awareness and Education on Mental Health The growing awareness and education surrounding mental health issues in India are pivotal drivers for the neuropsychiatric disorders-treatment market. Campaigns aimed at destigmatizing mental health have gained traction, leading to increased public discourse and understanding. Educational institutions and workplaces are increasingly incorporating mental health education, which encourages individuals to seek help. This cultural shift is reflected in the rising number of consultations with mental health professionals. As awareness continues to grow, the demand for effective treatment options is expected to rise, thereby expanding the neuropsychiatric disorders-treatment market. The emphasis on mental well-being is likely to foster a more supportive environment for those affected by neuropsychiatric disorders. ## Future Outlook The [Neuropsychiatric Disorders Treatment Market](https://www.marketresearchfuture.com/reports/neuropsychiatric-disorders-treatment-market-1281) is projected to grow at a 10.25% CAGR from 2025 to 2035, driven by increasing awareness, technological advancements, and rising mental health issues. **New opportunities:** - Development of telehealth platforms for remote patient monitoring - Investment in AI-driven diagnostic tools for early detection - Expansion of personalized medicine approaches in treatment protocols By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms. ## Segment Insights ### By Disorders: Degenerative Diseases (Largest) vs. Neurotic Disorders (Fastest-Growing) In the India neuropsychiatric disorders-treatment market, the segment values are distinctly characterized by their market share distribution. Degenerative Diseases hold the largest share, reflecting a significant portion of treatment demands. Meanwhile, Neurotic Disorders, while smaller in total share, showcase a robust and increasing presence, driven by rising awareness and improved diagnostics among healthcare professionals. The growth trends and drivers influencing these segments reveal key insights into market dynamics. The increasing prevalence of mental health issues and a growing aging population contribute to the expansion of Degenerative Diseases, whereas Neurotic Disorders are experiencing rapid growth due to changing lifestyles and increasing stress levels. The amalgamation of social, economic, and healthcare factors fuels this segment's potential for future growth. Degenerative Diseases (Dominant) vs. Neurotic Disorders (Emerging) Degenerative Diseases are recognized as the dominant force within the India neuropsychiatric disorders-treatment market, characterized by complex treatment regimens and a focus on long-term management. These conditions, including Alzheimer's and Parkinson's, necessitate specialized therapies and continuous support, which contributes to their prevalent status. In contrast, Neurotic Disorders, categorized as emerging within this market, are gaining traction due to rising rates of anxiety, depression, and stress-related conditions. This surge is largely influenced by modern lifestyle changes, prompting a shift towards more therapeutic interventions. As mental health awareness increases, Neurotic Disorders are expected to occupy a more significant market share, reflecting an evolving landscape where mental well-being is prioritized. ### By Treatment: Drug Treatment (Largest) vs. Shock Treatment (Fastest-Growing) In the India neuropsychiatric disorders-treatment market, the Drug Treatment segment holds the largest share, providing effective pharmacological interventions for various disorders. Shock Treatment, although currently smaller in market share, is recognized for its increasing adoption due to its rapid results in certain severe cases, indicating a shift in treatment preferences among practitioners. As healthcare professionals continue to explore comprehensive treatment approaches, the growth of the Shock Treatment segment is driven by advancements in technology and increased awareness of its benefits. Additionally, the rising prevalence of neuropsychiatric disorders propels demand for more varied treatment options. This trend suggests that while Drug Treatment remains dominant, the demand for faster and more effective interventions like Shock Treatment is on the rise, shaping the future landscape of treatment options. Drug Treatment: Dominant vs. Shock Treatment: Emerging The Drug Treatment segment is characterized by a wide range of pharmacological therapies that cater to various neuropsychiatric disorders, making it the most widely utilized option among practitioners. It includes antidepressants, antipsychotics, and mood stabilizers, offering tailored solutions for patients. In contrast, the Shock Treatment segment, though not as prevalent, represents an emerging approach that is gaining attention for its efficacy in acute scenarios. Healthcare providers are increasingly recognizing the significance of Shock Treatment as a viable option for patients who do not respond to traditional drug therapies, thus contributing to its rapid growth. The evolving landscape indicates a complementary relationship between these two treatment modalities, accommodating diverse patient needs. ### By End User: Hospitals (Largest) vs. Clinics (Fastest-Growing) In the India neuropsychiatric disorders-treatment market, the end user segment showcases hospitals as the predominant force, commanding substantial share due to their comprehensive diagnostic and treatment facilities. Clinics, on the other hand, are gaining momentum, especially in urban and suburban areas, as patients seek accessible treatment options for neuropsychiatric conditions. Their growth is further fueled by the increasing awareness of mental health, driving patients towards specialized outpatient care. Growth trends in this segment indicate a shift towards patient-centric care, with hospitals adapting to new treatment protocols and technologies while clinics expand their services. The rise of telemedicine and consultation services has also contributed to the rapid growth of clinics. As research in neuropsychiatric disorders progresses, research centres are expected to play a pivotal role, although their current market share remains modest compared to hospitals and clinics. Hospitals: Dominant vs. Clinics: Emerging Hospitals dominate the end user segment, offering a wide array of psychiatric services, including inpatient care and advanced treatment options. Their established infrastructure and ability to cater to severe cases of neuropsychiatric disorders make them the preferred choice for many patients. Conversely, clinics are emerging as vital players in the sector, providing personalized outpatient services that facilitate ongoing treatment and support. Their role is becoming increasingly important as they offer flexible appointment schedules and often utilize innovative treatment methodologies that appeal to a broader demographic. As both segments evolve, the dynamics between hospitals and clinics will likely redefine standard care protocols, emphasizing teamwork in patient management. ## Competitive Benchmarking The neuropsychiatric disorders-treatment market in India is characterized by a dynamic competitive landscape, driven by increasing prevalence rates of mental health conditions and a growing awareness of the importance of mental health care. Key players such as Johnson & Johnson (US), Pfizer (US), and Eli Lilly and Company (US) are actively shaping the market through strategic initiatives focused on innovation, partnerships, and regional expansion. These companies are leveraging their extensive research capabilities to develop novel therapies, thereby enhancing their competitive positioning in a market that is becoming increasingly fragmented yet competitive.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. The collective influence of these key players is significant, as they not only drive innovation but also set industry standards that smaller companies often follow. This competitive environment fosters a culture of continuous improvement and adaptation, which is essential in addressing the diverse needs of patients suffering from neuropsychiatric disorders. In October Johnson & Johnson (US) announced a strategic partnership with a leading Indian healthcare provider to enhance access to its innovative mental health therapies. This collaboration is expected to facilitate the distribution of their latest antipsychotic medication, which has shown promising results in clinical trials. The partnership underscores Johnson & Johnson's commitment to expanding its footprint in the Indian market while addressing the pressing need for effective treatment options. In September Pfizer (US) launched a new digital health platform aimed at improving patient engagement and adherence to treatment regimens for neuropsychiatric disorders. This initiative reflects Pfizer's focus on integrating technology into healthcare solutions, potentially transforming how patients interact with their treatment plans. By leveraging digital tools, Pfizer aims to enhance patient outcomes and streamline the management of neuropsychiatric conditions, thereby reinforcing its competitive edge in the market. In August Eli Lilly and Company (US) expanded its research and development efforts in India by establishing a new innovation hub dedicated to neuropsychiatric disorders. This hub is expected to focus on developing personalized treatment options, which may significantly impact the treatment landscape. Eli Lilly's investment in local R&D indicates a long-term commitment to understanding the unique challenges faced by Indian patients, positioning the company as a leader in tailored therapeutic solutions. As of November current trends in the neuropsychiatric disorders-treatment market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, ultimately enhancing patient care and treatment outcomes. ## Recent News & Developments The India Neuropsychiatric Disorders Treatment Market is witnessing significant developments, particularly in the pharmaceutical sector. Companies such as Sun Pharmaceutical Industries and Cipla have recently expanded their product portfolios to include innovative psychiatric treatments, aiming to address the rising demand caused by increasing awareness and prevalence of mental health issues. Notably, in August 2023, Wockhardt announced a strategic partnership to enhance drug delivery mechanisms for neuropsychiatric medications, showcasing the focus on research and development in this sector. Additionally, in May 2022, Zydus Cadila launched a new formulation targeting depression and anxiety disorders, reflecting the growing emphasis on mental health treatments in India. Mergers and acquisitions have also marked the landscape; in September 2023, Piramal Enterprises acquired a specialty pharmaceutical unit from Abbott, India, which could potentially enhance its neuropsychiatric offerings. The growth in the market valuation of companies like Dr. Reddy's Laboratories and Intas Pharmaceuticals is indicative of the sector's vitality, with significant investments being funneled into R&D. The increasing recognition of mental health issues is likely to continue influencing the competitive dynamics among leading players such as GSK India, Torrent Pharmaceuticals, and Aurobindo Pharma, shaping the future of neuropsychiatric treatment in India. ## Report Scope | MARKET SIZE 2024 | 9.06(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 9.99(USD Billion) | | MARKET SIZE 2035 | 26.5(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.25% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Johnson & Johnson (US), Pfizer (US), Eli Lilly and Company (US), AstraZeneca (GB), Bristol-Myers Squibb (US), Novartis (CH), Sanofi (FR), Roche (CH), Otsuka Pharmaceutical (JP) | | Segments Covered | Disorders, Treatment, End User | | Key Market Opportunities | Integration of digital therapeutics and personalized medicine in the neuropsychiatric disorders-treatment market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition in the neuropsychiatric disorders-treatment market. | | Countries Covered | India | ## Frequently Asked Questions **Q: What was the market valuation of the India neuropsychiatric disorders-treatment market in 2024?** A: The market valuation was $9.06 Billion in 2024. **Q: What is the projected market valuation for the India neuropsychiatric disorders-treatment market by 2035?** A: The projected valuation for 2035 is $26.5 Billion. **Q: What is the expected CAGR for the India neuropsychiatric disorders-treatment market during the forecast period 2025 - 2035?** A: The expected CAGR during this period is 10.25%. **Q: Which segments are included in the India neuropsychiatric disorders-treatment market?** A: The segments include Degenerative Diseases, Neurotic Disorders, Psychosis, and Others. **Q: What are the projected values for Drug Treatment in the India neuropsychiatric disorders-treatment market?** A: The projected values for Drug Treatment range from $5.5 Billion to $16.0 Billion. **Q: Who are the key players in the India neuropsychiatric disorders-treatment market?** A: Key players include Johnson & Johnson, Pfizer, Eli Lilly and Company, and AstraZeneca. **Q: What is the projected value range for Neurotic Disorders in the market?** A: The projected value range for Neurotic Disorders is $3.0 Billion to $9.0 Billion. **Q: What are the expected values for hospitals as an end user in the market?** A: The expected values for hospitals range from $3.62 Billion to $10.45 Billion. **Q: What is the projected value range for Psychosis in the India neuropsychiatric disorders-treatment market?** A: The projected value range for Psychosis is $2.0 Billion to $6.0 Billion. **Q: What are the projected values for research centres as an end user in the market?** A: The projected values for research centres range from $1.81 Billion to $5.15 Billion. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-neuropsychiatric-disorders-treatment-market-45199*